Source: http://www.google.com/patents/US20010049543?ie=ISO-8859-1&dq=5,966,702
Timestamp: 2014-03-12 11:24:46
Document Index: 35256669

Matched Legal Cases: ['art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'application No. 60']

Patent US20010049543 - Method and apparatus for biventricular stimulation and capture monitoring - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsA multi-chamber stimulation device and associated method reliably and automatically verify capture during cardiac stimulation. The stimulation device achieves efficient synchronous biventricular stimulation by using cross-chamber electrode configurations to minimize pacing energy requirements, and further...http://www.google.com/patents/US20010049543?utm_source=gb-gplus-sharePatent US20010049543 - Method and apparatus for biventricular stimulation and capture monitoringAdvanced Patent SearchPublication numberUS20010049543 A1Publication typeApplicationApplication numberUS 09/847,703Publication dateDec 6, 2001Filing dateMay 1, 2001Priority dateMay 15, 2000Also published asDE60114507D1, DE60114507T2, EP1155711A2, EP1155711A3, EP1155711B1Publication number09847703, 847703, US 2001/0049543 A1, US 2001/049543 A1, US 20010049543 A1, US 20010049543A1, US 2001049543 A1, US 2001049543A1, US-A1-20010049543, US-A1-2001049543, US2001/0049543A1, US2001/049543A1, US20010049543 A1, US20010049543A1, US2001049543 A1, US2001049543A1InventorsMark KrollOriginal AssigneeKroll Mark W.Export CitationBiBTeX, EndNote, RefManReferenced by (43), Classifications (9), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetMethod and apparatus for biventricular stimulation and capture monitoringUS 20010049543 A1Abstract A multi-chamber stimulation device and associated method reliably and automatically verify capture during cardiac stimulation. The stimulation device achieves efficient synchronous biventricular stimulation by using cross-chamber electrode configurations to minimize pacing energy requirements, and further achieves reliable capture detection by using cross-chamber sensing electrode configurations to minimize the effect of lead polarization. During cross-chamber stimulation, a biphasic pulse, a balanced monophasic pulse, or a biventricular pacing pulse may be delivered. By delivering a biventricular pacing pulse, a larger potential difference is established across the ventricles, improving the recruitment of Purkinje fibers and other conductive elements of the cardiac tissue, thus enhancing conduction of the stimulating pulses through the cardiac tissue. Images(8) Claims(30)
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [0039] The following description is of a best mode presently contemplated for practicing the invention. This description is not to be taken in a limiting sense but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be ascertained with reference to the issued claims. In the description of the invention that follows, like numerals or reference designators will be used to refer to like parts or elements throughout. [0040]FIG. 1 illustrates a stimulation device 10 in electrical communication with a patient's heart 12 by way of three leads 20, 24 and 30 suitable for delivering multi-chamber stimulation and shock therapy. To sense atrial cardiac signals and to provide right atrial chamber stimulation therapy, the stimulation device 10 is coupled to an implantable right atrial lead 20 having at least an atrial tip electrode 22, which typically is implanted in the patient's right atrial appendage. [0041] To sense left atrial and ventricular cardiac signals and to provide left-chamber pacing therapy, the stimulation device 10 is coupled to a �coronary sinus� lead 24 designed for placement in the �coronary sinus region� via the coronary sinus so as to place a distal electrode adjacent to the left ventricle and additional electrode(s) adjacent to the left atrium. As used herein, the phrase �coronary sinus region� refers to the vasculature of the left ventricle, including any portion of the coronary sinus, great cardiac vein, left marginal vein, left posterior ventricular vein, middle cardiac vein, and/or small cardiac vein or any other cardiac vein accessible by the coronary sinus. [0042] Accordingly, the coronary sinus lead 24 is designed to receive atrial and ventricular cardiac signals and to deliver: left ventricular pacing therapy using at least a left ventricular tip electrode 26, left atrial pacing therapy using at least a left atrial ring electrode 27, and shocking therapy using at least a left atrial coil electrode 28. For a more detailed description of a coronary sinus lead, reference is made to U.S. patent application Ser. No. 09/457,277, titled �A Self-Anchoring Steerable Coronary Sinus Lead� (Pianca et. al), and U.S. Pat. No. 5,466,254, titled �Coronary Sinus Lead with Atrial Sensing Capability� (Helland), which patent application and patent are incorporated herein by reference. The stimulation device 10 is also shown in electrical communication with the patient's heart 12 by way of an implantable right ventricular lead 30 having, in this embodiment, a right ventricular tip electrode 32, a right ventricular ring electrode 34, a right ventricular (RV) coil electrode 36, and an SVC coil electrode 38. Typically, the right ventricular lead 30 is transvenously inserted into the heart 12 so as to place the right ventricular tip electrode 32 in the right ventricular apex so that the RV coil electrode 36 will be positioned in the right ventricle and the SVC coil electrode 38 will be positioned in the superior vena cava. Accordingly, the right ventricular lead 30 is capable of receiving cardiac signals, and delivering stimulation in the form of pacing and shock therapy to the right ventricle. While a preferred embodiment of the present invention is intended for use in a biventricular pacing and sensing mode employing coronary sinus lead 24 and right ventricular lead 30, the teaching of the present invention are not limited to this specific implementation. [0043]FIG. 2 illustrates a simplified block diagram of the multi-chamber implantable stimulation device 10, which is capable of treating both fast and slow arrhythmias with stimulation therapy, including cardioversion, defibrillation, and pacing stimulation. While a particular multi-chamber device is shown, this is for illustration purposes only, and one of skill in the art could readily duplicate, eliminate or disable the appropriate circuitry in any desired combination to provide a device capable of treating the appropriate chamber(s) with cardioversion, defibrillation and/or pacing stimulation. [0044] The stimulation device 10 includes a housing 40 which is often referred to as �can�, �case� or �case electrode�, and which may be programmably selected to act as the return electrode for all �unipolar� modes. The housing 40 may further be used as a return electrode alone or in combination with one or more of the coil electrodes 28, 36, or 38, for shocking purposes. The housing 40 further includes a connector (or a plurality of connectors 150, 152, 154, as it will be described in connection with FIG. 4) having a plurality of terminals, 42, 43, 44, 45, 46, 48, 52, 54, 56, and 58. For convenience, the names of the electrodes to which they are connected are shown next to the corresponding terminals. As an example, to achieve right atrial sensing and pacing, the connector includes at least a right atrial tip terminal 42 adapted for connection to the atrial (AR) tip electrode 22. [0045] To achieve left chamber sensing, pacing and/or shocking, the connector includes at least a left ventricular (VL) tip terminal 44, a left ventricular (VL) ring terminal 45, and a left atrial (AL) ring terminal 46, and a left atrial (AL) shocking terminal (coil) 48, which are adapted for connection to the left ventricular tip electrode 26, the left atrial tip electrode 27, and the left atrial coil electrode 28, respectively. [0046] To support right chamber sensing, pacing and/or shocking, the connector further includes a right ventricular (VR) tip terminal 52, a right ventricular (VR) ring terminal 54, a right ventricular (RV) shocking terminal (coil) 56, and an SVC shocking terminal (coil) 58, which are adapted for connection to the right ventricular tip electrode 32, right ventricular ring electrode 34, the RV coil electrode 36, and the SVC coil electrode 38, respectively. [0047] In the embodiment of FIGS. 1 and 2, and as further illustrated in FIG. 4, the stimulation device 10 is illustrated to include three bipolar connection ports 150, 152, 154. A left ventricular/atrial connection port (LV/LA connection port) 150 accommodates the left ventricular lead (LV lead) 24 with terminals 44, 45, 46, 48 that are associated with the left ventricular tip electrode (LV tip electrode) 26, the left ventricular ring electrode (LV ring electrode) 25, the left atrial ring electrode (LA ring electrode) 27, and the left atrial coil electrode (LA coil electrode) 28, respectively. [0048] A right ventricular connection port (RV connection port) 152 accommodates the right ventricular lead (RV lead) 30 with terminals 52, 54, 56, 58 that are associated with the right ventricular tip electrode (RV tip electrode) 32, the right ventricular ring electrode (RV ring electrode) 34, the right ventricular coil electrode (RVCE) 36, and the right ventricular SVC coil electrode (RV SVC coil electrode) 38, respectively. [0049] A right atrial connection port (RA connection port) 154 accommodates the right atrial lead (RA lead) 20 with terminals that are associated with the right atrial tip electrode (RA tip electrode) 22 and the right atrial ring electrode (RA ring electrode) 23, respectively. [0050] It is recognized that numerous variations exist in which combinations of unipolar, bipolar and/or multipolar leads may be positioned at desired locations within the heart in order to provide multichamber or multisite stimulation. [0051] At the core of the stimulation device 10 is a programmable microcontroller 60 that controls the various modes of stimulation therapy. As is well known in the art, the microcontroller 60 typically includes a microprocessor, or equivalent control circuitry, designed specifically for controlling the delivery of stimulation therapy, and may further include RAM or ROM memory, logic and timing circuitry, state machine circuitry, and I/O circuitry. Typically, the microcontroller 60 includes the ability to process or monitor input signals (data) as controlled by a program code stored in a designated block of memory. The details of the design and operation of the microcontroller 60 are not critical to the present invention. Rather, any suitable microcontroller 60 may be used that carries out the functions described herein. The use of microprocessor-based control circuits for performing timing and data analysis functions are well known in the art. [0052] Representative types of control circuitry that may be used with the present invention include the microprocessor-based control system of U.S. Pat. No. 4,940,052 (Mann et. al), and the state-machine of U.S. Pat. No. 4,712,555 (Sholder) and U.S. Pat. No. 4,944,298 (Sholder). For a more detailed description of the various timing intervals used within the stimulation device and their inter-relationship, refer to U.S. Pat. No. 4,788,980 (Mann et. al). These patents (U.S. Pat. Nos. 4,940,052; 4,712,555; 4,944,298; and 4,788,980) are incorporated herein by reference. [0053] As shown in FIG. 2, an atrial pulse generator 70 and a ventricular pulse generator 72 generate pacing stimulation pulses for delivery by the right atrial lead 20, the right ventricular lead 30, and/or the coronary sinus lead 24 via a switch bank 74. It is understood that in order to provide stimulation therapy in each of the four chambers of the heart, the atrial pulse generator 70 and the ventricular pulse generator 72 may include dedicated, independent pulse generators, multiplexed pulse generators, or shared pulse generators. The atrial pulse generator 70 and the ventricular pulse generator 72 are controlled by the microcontroller 60 via appropriate control signals 76 and 78, respectively, to trigger or inhibit the stimulation pulses. [0054] The microcontroller 60 further includes timing control circuitry 79 which is used to control the timing of such stimulation pulses (e.g. pacing rate, atrio-ventricular (AV) delay, atrial interconduction (A-A) delay, or ventricular interconduction (V-V) delay, etc.), as well as to keep track of the timing of refractory periods, PVARP intervals, noise detection windows, evoked response windows, alert intervals, marker channel timing, etc. [0055] In one embodiment of the present invention, the switch bank 74 includes a plurality of switches for connecting the desired electrodes to the appropriate I/O circuits, thereby providing complete electrode programmability. Accordingly, the switch bank 74, in response to a control signal 80 from the microcontroller 60, determines the polarity of the stimulation pulses (e.g. unipolar, bipolar, cross-chamber, etc.) by selectively closing the appropriate combination of switches (not shown) as is known in the art. [0056] Atrial sensing circuits 82 and ventricular sensing circuits 84 may also be selectively coupled to the right atrial lead 20, coronary sinus lead 24, and the right ventricular lead 30, through the switch bank 74, for detecting the presence of cardiac activity in each of the four chambers of the heart. Accordingly, the atrial and ventricular sensing circuits 82 and 84 may include dedicated sense amplifiers, multiplexed amplifiers, or shared amplifiers. [0057] The ventricular sensing circuits 84 are coupled to the coronary sinus lead 24 and the right ventricular lead 30 through switch bank 74 for detecting the presence of cardiac activity within the right and/or left ventricles. The switch bank 74 determines the �sensing polarity� of the cardiac signal by selectively closing the appropriate switches. In this way, the clinician may program the sensing polarity independent of the stimulation polarity. The electrode programmability includes selection of the pacing polar configuration, selection of the sensing polar configuration as well as designation of the positive, negative or indifferent poles for each polar configuration. [0058] Each of the atrial sensing circuit 82 or the ventricular sensing circuit 84 preferably employs one or more low power, precision amplifiers, each with programmable gain and/or automatic gain control, bandpass filtering, and a threshold detection circuit, to selectively sense the cardiac signal of interest. The automatic gain control enables the stimulation device 10 to deal effectively with the difficult problem of sensing the low amplitude signal characteristics of atrial or ventricular fibrillation. [0059] The outputs of the atrial and ventricular sensing circuits 82 and 84 are connected to the microcontroller 60 for triggering or inhibiting the atrial and ventricular pulse generators 70 and 72, respectively, in a demand fashion, in response to the absence or presence of cardiac activity, respectively, in the appropriate chambers of the heart. The atrial and ventricular sensing circuits 82 and 84, in turn, receive control signals over signal lines 86 and 88 from the microcontroller 60, for controlling the gain, threshold, polarization charge removal circuitry (not shown), and the timing of any blocking circuitry (not shown) coupled to the inputs of the atrial and ventricular sensing circuits 82 and 84. [0060] For arrhythmia detection, the stimulation device 10 includes an arrhythmia detector 77 (FIG. 2) that utilizes the atrial and ventricular sensing circuits 82 and 84 to sense cardiac signals, for determining whether a rhythm is physiologic or pathologic. As used herein �sensing� is reserved for the noting of an electrical signal, and �detection� is the processing of these sensed signals and noting the presence of an arrhythmia. The timing intervals between sensed events (e.g. P-waves, R-waves, and depolarization signals associated with fibrillation which are sometimes referred to as �F-waves� or �Fib-waves�) are then classified by the microcontroller 60 by comparing them to a predefined rate zone limit (e.g. bradycardia, normal, low rate VT, high rate VT, and fibrillation rate zones) and various other characteristics (e.g. sudden onset, stability, physiologic sensors, and morphology, etc.) in order to determine the type of remedial therapy that is needed (e.g. bradycardia pacing, anti-tachycardia pacing, cardioversion shocks or defibrillation shocks, collectively referred to as �tiered therapy�). [0061] Cardiac signals are also applied to the inputs of an analog-to-digital (A/D) data acquisition system 90. The data acquisition system 90 is configured to acquire intracardiac electrogram signals, convert the raw analog data into digital signals, and store the digital signals for later processing and/or telemetric transmission to an external device 102. The data acquisition system 90 is coupled to the right atrial lead 20, the coronary sinus lead 24, and the right ventricular lead 30 through the switch bank 74 to sample cardiac signals across any pair of desired electrodes. [0062] Advantageously, the data acquisition system 90 may be coupled to the microcontroller 60 or another detection circuitry, for detecting an evoked response from the heart 12 in response to an applied stimulus, thereby aiding in the detection of �capture�. Capture occurs when an electrical stimulus applied to the heart is of sufficient energy to depolarize the cardiac tissue, thereby causing the heart muscle to contract. The microcontroller 60 detects a depolarization signal during a window following a stimulation pulse, the presence of which indicates that capture has occurred. The microcontroller 60 includes an automatic capture detector 65 that enables capture detection by triggering the ventricular pulse generator 72 to generate a stimulation pulse, starting a capture detection window using the timing circuitry within the microcontroller 60, and enabling the data acquisition system 90 via control signal 92 to sample the cardiac signal that falls in the capture detection window and, based on the amplitude of the sampled cardiac signal, determines if capture has occurred. [0063] The microcontroller 60 is further coupled to a memory 94 by a suitable data/address bus 96, wherein the programmable operating parameters used by the microcontroller 60 are stored and modified, as required, in order to customize the operation of the stimulation device 10 to suit the needs of a particular patient. Such operating parameters define, for example, pacing pulse amplitude, pulse duration, electrode polarity, rate, sensitivity, automatic features, arrhythmia detection criteria, and the amplitude, waveshape and vector of each shocking pulse to be delivered to the patient's heart 12 within each respective tier of therapy. A feature of the stimulation device 10 is the ability to sense and store a relatively large amount of data (e.g. from the data acquisition system 90), which data may then be used for subsequent analysis to guide the programming of the stimulation device 10. [0064] Advantageously, the operating parameters of the stimulation device 10 may be non-invasively programmed into the memory 94 through a telemetry circuit 100 in telemetric communication with the external device 102, such as a programmer, transtelephonic transceiver, or a diagnostic system analyzer. The telemetry circuit 100 is activated by the microcontroller 60 by a control signal 106. The telemetry circuit 100 advantageously allows intracardiac electrograms and status information relating to the operation of the stimulation device 10 (as contained in the microcontroller 60 or memory 94) to be sent to the external device 102 through the established communication link 104. [0065] The stimulation device 10 may further include a physiologic sensor 108, commonly referred to as a �rate-responsive� sensor because it is typically used to adjust pacing stimulation rate according to the exercise state of the patient. However, the physiological sensor 108 may further be used to detect changes in cardiac output, changes in the physiological condition of the heart, or diurnal changes in activity (e.g. detecting sleep and wake states). Accordingly, the microcontroller 60 responds by adjusting the various pacing parameters (such as rate, AV Delay, V-V Delay, etc.) at which the atrial and ventricular pulse generators 70 and 72 generate stimulation pulses. [0066] While the physiologic sensor 108 is shown as being included within the stimulation device 10, it is to be understood that the physiologic sensor 108 may alternatively be external to the stimulation device 10, yet still be implanted within, or carried by the patient. A common type of rate responsive sensor is an activity sensor, such as an accelerometer or a piezoelectric crystal, which is mounted within the housing 40 of the stimulation device 10. Other types of physiologic sensors are also known, for example, sensors which sense the oxygen content of blood, respiration rate and/or minute ventilation, pH of blood, ventricular gradient, etc. However, any sensor may be used which is capable of sensing a physiological parameter which corresponds to the exercise state of the patient. [0067] The stimulation device 10 additionally includes a power source such as a battery 110 that provides operating power to all the circuits shown in FIG. 2. For the stimulation device 10, which employs shocking therapy, the battery 110 must be capable of operating at low current drains for long periods of time, and also be capable of providing high-current pulses (for capacitor charging) when the patient requires a shock pulse. The battery 110 must preferably have a predictable discharge characteristic so that elective replacement time can be detected. Accordingly, the stimulation device 10 can employ lithium/silver vanadium oxide batteries. [0068] The stimulation device 10 further includes a magnet detection circuitry (not shown), coupled to the microcontroller 60. The purpose of the magnet detection circuitry is to detect when a magnet is placed over the stimulation device 10, which magnet may be used by a clinician to perform various test functions of the stimulation device 10 and/or to signal the microcontroller 60 that an external programmer 102 is in place to receive or transmit data to the microcontroller 60 through the telemetry circuit 100. [0069] As further shown in FIG. 2, the stimulation device 10 is shown as having an impedance measuring circuit 112 which is enabled by the microcontroller 60 by a control signal 114. Certain applications for an impedance measuring circuit 112 include, but are not limited to, lead impedance surveillance during the acute and chronic phases for proper lead positioning or dislodgment; detecting operable electrodes and automatically switching to an operable pair if dislodgment occurs; measuring respiration or minute ventilation; measuring thoracic impedance for determining shock thresholds; measuring stroke volume; and detecting the opening of the valves, etc. The impedance measuring circuit 112 is advantageously coupled to the switch bank 74 so that any desired electrode may be used. In an alternative embodiment of the present invention, an impedance measurement circuit 112 is used for measuring cardiac impedance in a method of verifying capture. Changes in cardiac impedance associated with changes in heart chamber blood volume reflect the filling and ejection of blood from the heart. A cardiac impedance deflection results when the ventricles contract and eject blood can therefore be used in verifying that capture has occurred following a pacing pulse. In this embodiment, an excitation current pulse is applied between left ventricular (LV) tip electrode 26 and the right ventricular (RV) tip electrode 32 and the impedance measurement is made across left atrial (LA) ring electrode 27 and right ventricular (RV) ring electrode 34. [0070] It is a function of the stimulation device 10 to operate as an implantable cardioverter/defibrillator (ICD) device. That is, it must detect the occurrence of an arrhythmia, and automatically apply an appropriate electrical shock therapy to the heart aimed at terminating the detected arrhythmia. To this end, the microcontroller 60 further controls a shocking circuit 116 by way of a control signal 118. The shocking circuit 116 generates shocking pulses of low (up to 0.5 Joules), moderate (0.5-10 Joules), or high (11 to 40 Joules) energy, as controlled by the microcontroller 60. Such shocking pulses are applied to the patient's heart through at least two shocking electrodes, and as shown in this embodiment, selected from the left atrial coil electrode 28, the RV coil electrode 36, and/or the SVC coil electrode 38 (FIG. 1). As noted above, the housing 40 may act as an active electrode in combination with the RV electrode 36, or as part of a split electrical vector using the SVC coil electrode 38 or the left atrial coil electrode 28 (i.e., using the RV electrode as common electrode). [0071] Cardioversion shocks are generally considered to be of low to moderate energy level (so as to minimize pain felt by the patient), and/or synchronized with an R-wave and/or pertaining to the treatment of tachycardia. Defibrillation shocks are generally of moderate to high energy level (i.e., corresponding to thresholds in the range of 5-40 Joules), delivered asynchronously (since R-waves may be too disorganized), and pertaining exclusively to the treatment of fibrillation. Accordingly, the microcontroller 60 is capable of controlling the synchronous or asynchronous delivery of the shocking pulses. [0072] In this embodiment, a control program executed by microprocessor 60 is comprised of multiple integrated program modules, with each module bearing responsibility for controlling one or more functions of the stimulation device 10. For example, one program module may control the delivery of stimulating pulses to the heart 12, while another may control the verification of ventricular capture and ventricular pacing energy determination. In effect, each program module is a control program dedicated to a specific function or set of functions of the stimulation device 10. [0073] Having described the environment in which the present invention operates, an exemplary preferred embodiment of the present invention will now be described in detail. FIG. 4 is an illustration depicting an equivalent circuit diagram of the electrode configuration used for biventricular pacing in accordance with a preferred embodiment of the present invention. A cross-chamber electrode configuration, defined as a polarity configuration comprising two or more electrodes existing on at least two different lead bodies located in two different heart chambers, is used for cross-ventricular pacing. A pacing pulse is delivered by the ventricular pulse generator 72 between the left ventricular (VL) tip electrode 26 and the right ventricular (VR) tip electrode 32. To maintain a potential difference between these two tip electrodes 26 and 32, the ventricular pacing pulse is inverted by an inverter 122 prior to delivering the pulse to the right ventricular (VR) tip electrode 32. A positive pacing pulse 210 is delivered to the left ventricular (VL) tip electrode 26 and a negative pacing pulse 212 is delivered to the right ventricular (VR) tip electrode 32. Thus, a cross-chamber, biventricular pacing configuration is provided. [0074] Such a configuration could be referred to as �pseudo unipolar� since stimulation is performed between two electrodes not located on the same lead body and not involving the can 40, but rather in different cardiac chambers, yet each electrode effectively activates its respective chamber. The potential difference between the left ventricular (VL) tip electrode 26 and the right ventricular (VR) tip electrode 32 will result in conduction of the stimulating pulse through the conductive elements of the cardiac tissues, for example the Purkinje fibers, and the intercalated discs of the myocardial cells, causing depolarization in both ventricles, thereby achieving synchronous biventricular pacing. [0075] This conductive pathway is represented by an equivalent circuit 200. Besides the conductive elements of the cardiac tissues mentioned above, the equivalent circuit 200 also includes a capacitive element 220 associated with the left ventricular (VL) tip electrode 26 and a capacitive element 222 associated with the right ventricular (VR) tip electrode 32. In this equivalent circuit 200 the characteristic tissue impedance of the left ventricular tissue is generally represented by a resistive element ZLV 230, and the characteristic tissue impedance of the right ventricular tissue is generally represented by a resistive element ZRV 232. [0076] Since the tip electrodes 26 and 32 are in relatively close proximity to each other and are approximated by excitable cardiac tissue including myocardial cells, the Purkinje fibers, and cardiac bundles, direct conduction of excitation pulses is possible between the two ventricles. Furthermore, since this conductive pathway is not dependent on the right or left bundle branches extending into the left ventricle and the right ventricle from the Bundle of His and the atrioventricular node, ventricular stimulation in this cross-chamber configuration is less interrupted by cardiac conduction disorders such as Bundle Branch Block associated with conduction disease or aging that can affect the heart's normal conduction pathways. [0077] The advantages of this cross-chamber pacing configuration are: 1) the stimulation energy required is expected to be much less than that required for true unipolar pacing, and 2) the left and right ring electrodes 27 and 34 located on the coronary sinus lead 24 and RV lead 30, respectively, are not used for stimulation. Since these two ring electrodes 27 and 34 do not become polarized during a ventricular stimulation pulse (i.e., Vpace) as they would during bipolar stimulation, they are advantageously available for sensing the evoked response immediately following the stimulation pulse as will be described later in detail. [0078] A further aspect of the present invention is the programmable selection of the direction of current flow between the stimulating electrodes 26, 32. In the embodiment shown in FIG. 4, the direction of the current flow will be from the right ventricular (VR) tip electrode 34 to the left ventricular (VL) tip electrode 26 since the negative going pulse is applied to the right ventricular (VR) tip electrode 32, and the positive going pulse is applied to the left ventricular (VL) tip electrode 26. By selectively applying the reverse voltage polarity, that is the negative going pulse to the left ventricular (VL) tip electrode 26, and the positive going pulse to the right ventricular (VR) tip electrode 32, the direction of the current flow will be reversed. Hence, the sequence of myocardial tissue activation can be influenced by selecting the direction of current flow. This selection allows specificity of activation sequence based on the patient's need. For example, in a patient suffering from dilated cardiomyopathy, typically the left ventricle is predominately affected in the earlier stages of the disease. The dilated left ventricle has diminished contractility causing its contraction to be slower and weaker than the still healthy right ventricle. Thus, by selecting the stimulation pathway direction from the left ventricle to the right ventricle, the slower left ventricle contraction is initiated prior to the faster right ventricle contraction, yielding superior synchronization of right ventricle and left ventricle contractions. [0079] A further aspect of the present invention is the selection of the pacing pulse morphology. In the embodiment of FIG. 4, a biventricular pacing pulse is illustrated where a positive going pulse 210 is applied to one electrode and a negative going pulse 212 is applied to a second electrode. Other pacing pulse morphologies are possible. For example, a balanced monophasic pacing pulse, or a biphasic pacing pulse could be applied to one electrode tip while the other electrode tip remains neutral, functioning as the return path for the conducted current. [0080] Yet a further aspect of the present invention is the enhancement of electrode tip geometry such that capacitive coupling between the points of electrode contact is increased, thereby improving the conductivity directly between the right and left tip electrodes 26 and 32, respectively. Such enhancement is preferably achieved by manufacturing the electrode tip with a rough surface to increase its surface area. [0081]FIG. 5 depicts an exemplary sensing configuration for a biventricular stimulation system in accordance with the present invention. Ventricular sensing circuitry 84 samples the myoelectric signal between the left atrial (AL) ring electrode 27 and the right ventricular (VR) ring electrode 34. Thus a cross-chamber, cross-ventricular sensing configuration is provided. Ventricular pulse generator 72 (FIG. 2) delivers pacing pulses via the left and right tip electrodes 26 and 32, respectively, as described earlier in conjunction with FIG. 4. In this way, the cross-chamber sensing configuration is not impaired by lead polarization effects, thus providing a superior sensing configuration for detecting and verifying capture. [0082] The left ventricular (VL) tip electrode 26 and left atrial (AL) ring electrode 27 can be connected to the stimulation device 10 via a single lead body 24 (FIG. 1), with bipolar connections to the left ventricular (VL) tip terminal 44 and the atrial ring terminal 46. The right ventricular (VR) tip electrode 32 and the right ventricular (VR) ring electrode 34 are connected to the stimulation device 10 via a single lead body 30 (FIG. 1), with bipolar connections to the right ventricular (VR) tip terminal 52 and the right ventricular (VR) ring terminal 54. [0083] Continuous automatic capture verification is performed by sampling the signal received on the left and right ring electrodes 27 and 34, respectively, following delivery of a ventricular stimulation pulse (Vpace) on the left and right tip electrodes 26 and 32, respectively. Essentially, cross-ventricular sensing of the evoked R-wave is achieved. Using this cross-chamber sensing configuration, the R-wave depolarization in the left ventricle and the R-wave depolarization in the right ventricle will be sensed as a single complex as illustrated by the internal electromyogram (IEGM) recordings in FIGS. 7 and 8. [0084]FIG. 7 illustrates a situation of loss of capture, where a stimulation pulse 134 is followed by a time delay 136 followed by an intrinsic response 138 is observed. FIG. 8 illustrates a situation of simultaneous capture in both the left and right ventricles. In this case, a stimulation pulse 150 is of sufficient energy to depolarize the cardiac tissue, resulting in a large evoked response 152 immediately following the stimulation pulse 150. [0085] With further reference to FIG. 2, the IEGM signal received by ventricular sensing circuitry 84 is analyzed by the microcontroller 60 for determination of capture. A morphology detector 64 can be used to compare specific characteristics of the sampled signal with specific characteristics of an evoked response signal 152. Such characteristics include slope, event width, time to onset, and similar parameters. The overall signal morphology can also be compared to an evoked response signal template stored in memory 94. An appropriate method using signal morphology analysis for signal detection is generally described in U.S. Pat. No. 4,817,605 to Sholder, which is incorporated herein by reference. [0086] Yet a further aspect of the present invention is a programmable selection of cross-chamber, unipolar, or bipolar sensing. The embodiment illustrated in FIG. 5 allows cross-chamber sensing of the R-wave produced in both ventricles using a unique cross-chamber electrode configuration. However, other cross-chamber sensing configurations are possible that will satisfy the object of the present invention in reliably sensing the evoked response. One such alternative sensing configuration is illustrated in FIG. 6, according to which, biventricular stimulation is performed in similar configuration as in FIG. 5, however biventricular bipolar sensing is performed in the left ventricle between the left atrial (AL) ring electrode 27 (or a ventricular ring electrode (not shown)) and the left ventricular (VL) tip electrode 26, and in the right ventricle between the right ventricular (VR) ring electrode 34 and the right ventricular (VR) tip electrode 32. [0087] In practice, the medical practitioner will program the pacing polarity and direction by designating each electrode as a positive pole (or ground), a negative pole, or an inactive (unused) pole during stimulation. Likewise, the medical practitioner will program the sensing polarity and direction by designating each electrode as a positive pole, a negative pole, or inactive pole during sensing. As an illustrative example: If the left atrial (AL) ring electrode 27 is programmed to be positive(+), the right ventricular (VR) ring electrode 34 is programmed to be negative (−), the left ventricular (VL) tip electrode 26, and the right ventricular (VR) tip electrode 34 and the can case 40 (FIG. 2) are programmed to be inactive, then a cross-chamber sensing configuration from the right ventricle relative to the left ventricle has been selected. [0088] Tables I and II below show additional illustrative examples of possible unipolar and bipolar combinations, where RV designates right ventricle, LV designates left ventricle, RA designates right atrium, and LA designates left atrium. The resulting polarities, sensing and stimulation pathway directions for various sensing configurations are shown based on the programmed electrode designation of: positive (+), negative (−), or inactive (0). TABLE I LA ring 27 or RV LV RV tip ring LV tip ring Can Stimulation Direction 32 34 26 25 40 Cross- Right to Left − 0 + 0 0 chamber Cross- Left to Right + 0 − 0 0 chamber [0089] TABLE II LA ring 27 or RV LV RV tip ring LV tip ring Can Sensing Direction 32 34 26 25 40 Cross- Right to Left 0 − 0 + 0 chamber Cross- Left to Right 0 + 0 − 0 chamber Bipolar both (convention − + − + 0 chambers al) [0090] In another embodiment, impedance measurements can be made by an impedance measurement circuitry 112 (FIG. 2) for capture verification rather than evoked response detection from the IEGM. The use of the four electrode terminals (26, 27, 32, 34) on the coronary sinus lead 24 and the right ventricular lead 30, makes possible a highly sensitive cardiac impedance measurement. The equivalent circuit diagram of FIG. 9 illustrates the measurement configuration. The application of an excitation current pulse 280 across the left ventricular (VL) tip electrode 26 and the right ventricular (VR) tip electrode 32, generates a voltage differential VS 282 that can be measured across the left atrial (AL) ring electrode 27 and the right ventricular (VR) ring electrode 34. The impedance can then be calculated by the microprocessor 60 according to the following equation: Z=I/V, [0091] where Z is the impedance associated with the myocardial tissue and blood volume residing between the left ventricular (VL) tip electrode 26 and the right ventricular (VR) tip electrode 32, I is the applied excitation current pulse 280, and VS is the measured voltage differential 282 that appears across the left atrial (AL) ring electrode 27 and the right ventricular (VR) ring electrode 34. Since the impedance measurement is made directly across the ventricles, it provides a direct measure of cardiac impedance with minimal influence of changes in thoracic impedance due to respiration. This more direct measure holds an advantage over impedance measurements that are performed between a lead electrode and the pacemaker can since, in those measurements, thoracic impedance may contribute to the measured signal to the same degree or an even greater degree than the cardiac impedance. Considerable signal processing is then needed to filter out the impedance signal associated with respiration. [0092] During ventricular contraction, the cardiac impedance, Z, will change as a function of the changing blood volume in the heart chambers. Therefore, as blood is ejected from the right and left ventricles, the impedance will decrease and as the ventricles fill, the impedance will increase. Thus, a change in the measured impedance Z is a direct consequence of the actual mechanical contraction of the ventricles and serves as a reliable indication of capture. [0093]FIG. 10 is an illustration of the impedance signal change that may be measured during a ventricular contraction. The impedance Z is graphed along the Y-axis 296 versus time along the X-axis 295. The microprocessor 60 examines the impedance signal for specific characteristics that would indicate ventricular contraction has indeed occurred, such as the area of the curve 294, the peak slope dZ/dt 290, or the maximum peak deflection 292. [0094] In an alternative embodiment of the present invention, stimulation is performed in one ventricle and capture sensing is performed in the other ventricle. More specifically, bipolar pacing is performed in the right ventricle between the right ventricular (VR) tip electrode 32 and the right ventricular (VR) ring electrode 34. Bipolar sensing is then performed between the left ventricular (VL) tip electrode 26 and the left atrial (AL) ring electrode 27. [0095] When a supra-threshold pacing pulse is delivered, causing depolarization in the right ventricle, the depolarization wave will be conducted to the left ventricle via the conductive elements and the myocardial cells themselves. Thus, both ventricles are captured and this effect can be detected by sensing in the left ventricle using the non-polarized left ventricular (VL) tip electrode 26 and left atrial (AL) ring electrode 27. Such a mode of capture sensing is hereby referred to as �cross-tracking� in that sensing in one cardiac chamber is performed to verify capture due to pacing in another cardiac chamber. [0096] Such cross-tracking can be performed to continuously monitor for capture during ventricular pacing or during periodic automatic threshold tests. While pacing pulse energy is progressively decreased in one ventricle, loss of capture is detected by sensing in the other ventricle. Specific algorithms for performing threshold tests are known by those reasonable skilled in the art and will not be described in detail here. For more detail, reference is made to U.S. Pat. No. 5,766,229 to Bornzin, or U.S. provisional patent application No. 60/204,088, filed on May 15, 2000, both of which are incorporated herein by reference. [0097] Thus a cardiac stimulating device has been described that provides reliable and efficient biventricular stimulation and capture sensing using cross-chamber electrode configurations thereby avoiding the difficulties associated with lead polarization in accurately detecting evoked responses for verifying capture. One skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for the purposes of illustration and not of limitation. Referenced byCiting PatentFiling datePublication dateApplicantTitleUS6768924 *Jan 3, 2002Jul 27, 2004Cardiac Pacemakers, Inc.Method and apparatus for capture verification based on propagated electrical activityUS7024241 *Dec 5, 2002Apr 4, 2006Pacesetter, Inc.Pacing pulse waveforms that support simultaneous intracardiac signal sensing and analysisUS7113823 *Nov 26, 2003Sep 26, 2006Cardiac Pacemakers, Inc.Morphology-based optimization of cardiac resynchronization therapyUS7120494 *Feb 17, 2003Oct 10, 2006Cardiac Pacemakers, Inc.System and method for eliminating cross-talk due to far-field signalsUS7123963Oct 31, 2002Oct 17, 2006Medtronic, Inc.Method of automatic evoked response sensing vector selection using evoked response waveform analysisUS7177689Oct 26, 2001Feb 13, 2007Cardiac Pacemakers, Inc.Method and apparatus for capture verification and threshold determinationUS7190993Nov 4, 2003Mar 13, 2007Medtronic, Inc.Implantable medical device having optical fiber for sensing electrical activityUS7203542Dec 2, 2003Apr 10, 2007St. Jude Medical AbImplantable biventricular cardiac stimulator with capture monitoring by IECG analysisUS7215996Oct 4, 2002May 8, 2007St. Jude Medical AbBi-ventricular heart stimulating device, system and methodUS7233826 *Apr 25, 2003Jun 19, 2007Medtronic, Inc.Bi-ventricular and single-ventricle pacingUS7236825Apr 30, 2004Jun 26, 2007Medtronic, Inc.Cardiac activity sensing during pacing in implantable devicesUS7286876Sep 19, 2002Oct 23, 2007Cardiac Pacemakers, Inc.Template-based capture verification for multi-site pacingUS7299094Jan 29, 2003Nov 20, 2007Pacesetter, Inc.System and method for implementing autocapture within biventricular implantable cardiac stimulation systemsUS7305265 *Nov 24, 2003Dec 4, 2007Terumo Kabushiki KaishaHeart treatment equipment for treating heart failureUS7373202Mar 31, 2005May 13, 2008Pacesetter, Inc.Unipolar and bipolar lead cardiac pacemaker and method for inhibiting anode stimulationUS7412287Dec 22, 2003Aug 12, 2008Cardiac Pacemakers, Inc.Automatic sensing vector selection for morphology-based capture verificationUS7450990 *Oct 28, 2003Nov 11, 2008Biotronik Gmbh & Co. KgStimulation device with stimulation outcome monitoringUS7546161 *Jan 11, 2006Jun 9, 2009Pacesetter, Inc.Methods for loss of capture and fusion avoidance in biventricular pacing therapyUS7555340Apr 1, 2005Jun 30, 2009Cardiac Pacemakers, Inc.Electrogram morphology-based CRT optimizationUS7558628Jul 10, 2006Jul 7, 2009Cardiac Pacemakers, Inc.Morphology-based optimization of cardiac resynchronization therapyUS7561914 *Dec 20, 2005Jul 14, 2009Medtronic, Inc.Method of continuous capture verification in cardiac resynchronization devicesUS7565195Apr 11, 2005Jul 21, 2009Pacesetter, Inc.Failsafe satellite pacemaker systemUS7583998Jun 21, 2005Sep 1, 2009Cardiac Pacemakers, Inc.Multi-chamber cardiac capture detection using cross chamber sensingUS7634313Apr 11, 2005Dec 15, 2009Pacesetter, Inc.Failsafe satellite pacemaker systemUS7702388 *Feb 28, 2003Apr 20, 2010Cardiac Pacemakers, Inc.Cardiac therapy triggered by capture verificationUS7831303Jun 17, 2003Nov 9, 2010Medtronic, Inc.Cardiac pacing apparatus and method for continuous capture managementUS7873415 *Dec 10, 2007Jan 18, 2011Cardiac Pacemakers, Inc.Cardiac rhythm management system and methodUS7920920 *Aug 31, 2006Apr 5, 2011Pacesetter, Inc.Algorithm for capture detectionUS7941219 *Sep 8, 2006May 10, 2011Cardiac Pacemakers, Inc.Capture detection based on propagated depolarization from a remote pacing siteUS7979124 *Nov 16, 2006Jul 12, 2011Cardiac Pacemakers, Inc.Method and system for detecting capture using a coronary vein electrodeUS8078276Jun 30, 2009Dec 13, 2011Cardiac Pacemakers, Inc.Electrogram morphology-based CRT optimizationUS8116866Jul 6, 2009Feb 14, 2012Cardiac Pacemakers, Inc.Morphology-based optimization of cardiac resynchronization therapyUS8131357 *Apr 1, 2005Mar 6, 2012Boston Scientific Neuromodulation CorporationApparatus and methods for detecting migration of neurostimulation leadsUS8204594 *Dec 21, 2010Jun 19, 2012Cardiac Pacemakers, Inc.Cardiac rhythm management system and methodUS8364265Jan 8, 2007Jan 29, 2013Cardiac Pacemakers, Inc.Method and apparatus for capture verification and threshold determinationUS8396539Feb 16, 2007Mar 12, 2013Medtronic, Inc.Implantable medical device having optical fiber for sensing electrical activityUS8401665Apr 1, 2005Mar 19, 2013Boston Scientific Neuromodulation CorporationApparatus and methods for detecting position and migration of neurostimulation leadsUS8406880May 29, 2007Mar 26, 2013Cardiac Pacemakers, Inc.Template-based capture verification for multi-site pacingUS8417337Jul 13, 2009Apr 9, 2013Medtronic, Inc.Method of continuous capture verification in cardiac resynchronization devicesUS8583235Jun 12, 2012Nov 12, 2013Cardiac Pacemakers, Inc.Cardiac rhythm management system and methodUS20110224751 *May 10, 2011Sep 15, 2011Sathaye Alok SCapture detection based on propagated depolarization from a pacing siteWO2003051457A1 *Oct 4, 2002Jun 26, 2003Bjoerling AndersAn implantable heart stimulating device, a system including such a device and a manner of using the systemWO2007089176A1 *Jan 31, 2006Aug 9, 2007St Jude MedicalSystem and method for detecting electric events in chambers of a heart* Cited by examinerClassifications U.S. Classification607/28International ClassificationA61N1/368, A61N1/37, A61N1/362Cooperative ClassificationA61N1/3712, A61N1/3627, A61N1/368European ClassificationA61N1/37D2, A61N1/362CLegal EventsDateCodeEventDescriptionMay 1, 2001ASAssignmentOwner name: PACESETTER, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KROLL, MARK W.;REEL/FRAME:011780/0107Effective date: 20010501RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google